GlycoMimetics Data on GMI-1271 Treatment of Acetaminophen-Triggered Liver Toxicity to Be Presented at "Digestive Disease Week" Conference
The oral presentation, entitled "Alleviation of acute drug-induced liver
injury following acetaminophen overdose by therapeutic blockade of E-
selectin in preclinical mouse model," is scheduled for
"The results in this preclinical model of liver toxicity demonstrate
both the biological activity of GMI-1271 and the possible broader uses
of an E-selectin antagonist. While
About GMI-1271
GMI-1271 is designed to block E-selectin (an adhesion molecule on
vascular endothelial cells.) For its lead clinical indication, GMI-1271
is designed to prevent E-selectin from binding with acute myeloid
leukemia (AML) cells in ways that help the cancer cells evade the
effects of chemotherapy treatment. Preclinical research points to the
drug's potential role in moving cancerous cells out of the protective
environment of the bone marrow where they hide and escape the effects of
chemotherapy. By blocking E-selectin, GMI-1271 also may protect normal
blood-producing cells, and reduce the toxic side effects of chemotherapy
such as low white blood cell counts that make some patients more prone
to infections. GMI-1271 may also reduce mucositis (inflammation or
lesions in the intestinal tract and mouth), which can be a side effect
of chemotherapy.
About
View source version on businesswire.com: http://www.businesswire.com/news/home/20160425006459/en/
Investor Contact:
sannes@annesassociates.com
or
Media
Contact:
jamielacey@presscommpr.com
Source:
News Provided by Acquire Media